Learn More
Invitrogen™ ROCK1 Polyclonal Antibody

Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA587623
Description
Immunogen sequence: YSNRRYLSSA NPNDNRTSSN ADKSLQESLQ KTIYKLEEQL HNEMQLKDEM EQKCRTSNIK LDKIMKELDE EGNQRRNLES TVSQIEKEKM LLQHRINEYQ RKAEQENEKR RNVENEVSTL KDQLEDLKKV SQNSQLANEK LSQLQKQLEE ANDLLRTESD TAVRLRKSHT EMSKSISQLE SLNRELQERN RILENSKSQT DKDYYQLQAI LEAERRDRGH DSEMIGDLQA RITSLQEEVK HLKHNLEKVE GERKEAQDML N; Positive Samples: 293T, U-251MG, Jurkat, BT-474; Cellular Location: Cell membrane, Cell projection, Cytoplasm, Golgi apparatus membrane, Peripheral membrane protein, bleb, centriole, centrosome, cytoskeleton, lamellipodium, microtubule organizing center, ruffle.
ROCK1 is a serine/threonine kinase that regulates cell differentiation and migration. The Rho/ROCK pathway is involved in the progression of various human cancers. ROCK1 has been found to be a new Caspase-3 substrate. ROCK, one of the effectors of the small GTPase Rho, has recently been shown to contribute significantly to myosin light chain (MLC) activation through two pathways: direct phosphorylation of MLC and phosphorylation of MLC phosphatase, leading to its inhibition. The increase in cellular contractility that is necessary for apoptotic membrane blebbing implies sustained augmentation of MLC phosphorylation. ROCK-1 consists of an amino-terminal kinase domain and an inhibitory cysteine/histidine-rich C-terminal domain that is located within a pleckstrin-homology region. They are joined by a variable region that contains the Rho-binding domain. During apoptosis, ROCK-I is cleaved by caspase-3 at a conserved DETD1113/G sequence and its carboxy-terminal inhibitory domain is removed, resulting in deregulated and constitutive kinase activity. The caspase-3-mediated cleavage and activation of ROCK I induces phosphorylation of MLC and membrane blebbing, one of the first events in the execution phase of apoptosis.
Specifications
| ROCK1 | |
| Polyclonal | |
| Unconjugated | |
| Rock1 | |
| 1110055K06Rik; Ac2-154; Liver regeneration-related protein LRRG199; MGC131603; MGC43611; p150 RhoA-binding kinase ROK beta; p160 ROCK-1; p160ROCK; p160-ROCK; PRO0435; Renal carcinoma antigen NY-REN-35; Rho associated coiled-coil containing protein kinase 1; Rho kinase; Rho-associated coiled-coil containing protein kinase 1; Rho-associated coiled-coil forming kinase 1; Rho-associated kinase beta; rho-associated protein kinase 1; Rho-associated, coiled-coil containing protein kinase 1; rho-associated, coiled-coil-containing protein kinase 1; Rho-associated, coiled-coil-containing protein kinase I; ROCK1; ROCK-I | |
| Rabbit | |
| Affinity chromatography | |
| RUO | |
| 19877, 6093 | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Liquid |
| ELISA, Immunohistochemistry (Paraffin), Western Blot | |
| 1.1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide; pH 7.3 | |
| P70335, Q13464 | |
| Rock1 | |
| Recombinant fusion protein containing a sequence corresponding to amino acids 400-660 of human ROCK1 (NP_0053971). | |
| 100 μL | |
| Primary | |
| Human, Mouse, Rat | |
| Antibody | |
| IgG |
Your input is important to us. Please complete this form to provide feedback related to the content on this product.